	US 12,295,978 B2
	Recombinant plasma membrane-based vesicle, for treating cancer
Gi-Beom Kim, Seoul (KR); Yoo Soo Yang, Seoul (KR); In-San Kim, Seoul (KR); and Gihoon Nam, Seoul (KR)
Assigned to SHIFTBIO INC., Seoul (KR)
Appl. No. 16/967,074
Filed by SHIFTBIO INC., Seoul (KR)
PCT Filed Sep. 28, 2018, PCT No. PCT/KR2018/011504 § 371(c)(1), (2) Date Aug. 3, 2020, PCT Pub. No. WO2019/066535, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. 10-2017-0126202 (KR), filed on Sep. 28, 2017.
Prior Publication US 2021/0106632 A1, Apr. 15, 2021
Int. Cl. A61K 35/766 (2015.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC A61K 35/766 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01)]

15 Claims

1. A method of treatment comprising administering a therapeutically effective amount of a recombinant plasma membrane-based vesicle to a subject that has cancer, wherein:

(i) a vesicular stomatitis virus glycoprotein (VSV-G) mutated protein in which the 162nd amino acid, histidine, is substituted with arginine is introduced into the membrane of the vesicle and

(ii) the vesicle is free of other anti-cancer agents.